This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: September 29, 2009
Last updated: October 31, 2011
Last verified: October 2011
The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.

Condition Intervention Phase
Schizophrenia Drug: AZD8529 Drug: Placebo to match AZD8529 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms With AZD8529 in Patients With Schizophrenia

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Functional magnetic resonance imaging (fMRI) [ Time Frame: 1 fMRI on Day 4; 1 fMRI on Day 21 ]
  • Computerized neurocognitive tests [ Time Frame: 1 on Day -1; 1 on Day 1 and on Day 21 ]

Secondary Outcome Measures:
  • Positive and Negative Syndrome Scale (PANSS) [ Time Frame: Day-1; Day 4; Day 17; Day 21 ]
  • Electroencephalography (EEG) [ Time Frame: Day 4; Day 21 ]
  • Laboratory assessment: electrocardiogram (ECG), physical exam, vital signs, [ Time Frame: Labs at screening and on Days -1, 4, 17, 21, and 35; ECG at screening and Day 35; Physical Exam at screening and Day 35; Vital signs at screening and Days -1,4, 17, 21, and 35 ]
  • Suicidality assessment, collection of adverse events [ Time Frame: Suicidality assesment at screening; and Days -1, 4, 17, 21, and 35 Adverse events at screening, and Days -1,4,17,21, and 35 ]

Enrollment: 59
Study Start Date: November 2009
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
80 mg AZD8529
Drug: AZD8529
2 capsules by mouth for 3 days
Placebo Comparator: 2
Drug: Placebo to match AZD8529
2 capsules by mouth for 3 days


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • DSM-IV diagnosis of schizophrenia or schizoaffective disorder

Exclusion Criteria:

  • ECT in the last 6 months
  • Substance abuse or dependence
  • History of claustrophobia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00986531

United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
Sponsors and Collaborators
Principal Investigator: Raquel Gur Hospital of the University of Pennsylvania, Dept of Psychiatry, Neuropsychiatry Section
  More Information

Responsible Party: AstraZeneca Identifier: NCT00986531     History of Changes
Other Study ID Numbers: D2285M00016
Study First Received: September 29, 2009
Last Updated: October 31, 2011

Keywords provided by AstraZeneca:
early phase trials

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders processed this record on September 21, 2017